Treatment guide for skin and soft tissue infections;Guía de tratamiento de las infecciones de piel y tejidos blandos

Revista Espanola de Quimioterapia

Volumn 19, Issue 4, 2006, Pages 378-394

  Garcia Rodriguez J A ^a   Mensa Pueyo, J ^b   Picazo De La Garza, J J ^c   Barberan Lopez J ^d   Serrano Heranz, R ^e   Artero, A ^f   Guirao Garriga, X ^g   Arias Diaz J ^c  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d HOSPITAL CENTRAL DE LA DEFENSA GÓMEZ ULLA   (Spain)

^e HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^f HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^g HOSPITAL GENERAL DE GRANOLLERS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; CEFALEXIN; CEFAZOLIN; CEPHALOSPORIN; CIPROFLOXACIN; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; ERTAPENEM; FUSIDIC ACID; GATIFLOXACIN; GLYCOPEPTIDE; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; PSEUDOMONIC ACID; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN;

CELLULITIS; DIABETES MELLITUS; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DRUG EFFICACY; ERYSIPELAS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMPETIGO; MICROBIOLOGICAL EXAMINATION; MONOTHERAPY; POSTOPERATIVE PERIOD; PRESCRIPTION; PYOMYOSITIS; REVIEW; SURGICAL INFECTION; SURGICAL TECHNIQUE; ULCER;

ALGORITHMS; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; BITES AND STINGS; COMBINED MODALITY THERAPY; DEBRIDEMENT; DERMATOMYCOSES; DISEASE MANAGEMENT; HUMANS; IMMUNOCOMPROMISED HOST; LYMPHEDEMA; NECROSIS; PRESSURE ULCER; SKIN DISEASES, INFECTIOUS; SOFT TISSUE INFECTIONS; WOUND INFECTION;

EID: 33846880915     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (137)

1. Nichols, R.L., Florman, S. Clinical presentations of soft tissue infections and surgical site infections. Clin Infect Dis 2001; 33 (Suppl. 2): S84-S93.
2. Centers for Disease Control. Incidence of soft tissue infections: San Francisco General Hospital 1996-2000. MWWR 2001; 50: 381-384.
3. Bowler, P.G., Duerden, B.I., Armstrong, D.G. Wound microbiology and associated approaches to wound management. Clin Microbiol Rev 2001; 14: 244-269.
4. Picazo, J.J., Betriu, C., Rodríguez-Avial, I., Azahares, E., Sánchez, B.A. y Grupo VIRA. Vigilancia de resistencias a los antimicrobianos: Estudio VIRA. Enferm Infecc Microbiol Clin 2002; 20: 503-510.
5. Cosgrove, S.E., Sakoulas, G., Perencevich, E.N, Schwaber, M.J., Karchmer, A.W., Carmeli, Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: A meta-analysis. Clin Infect Dis 2003; 36: 53-59.
6. Cosgrove, S.E., Carmeli, Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 2003; 36: 1433-1437.
7. Cuevas, O., Cercenado, E., Vindel, A. y cols. Evolution of the antimicrobial resistance of Staphylococcus spp. in Spain: Five Nationwide Prevalence Studies, 1986 to 2002. Antimicrob Agents Chemother 2004; 484240-484245.
8. Proyecto EPINE 10 años, 1990-99. http://db.doyma.es/cgi-bin/wdbcgi. exe/doyma/go?pag=http://www.mpsp.org/mpsp/epine/index.html.
9. Picazo, J.J., Betriu, C., Rodríguez-Avial, I. y cols. Vigilancia de resistencias a los antimicrobianos: Estudio VIRA 2006. Enferm Infecc Microbiol Clin (en prensa).
10. Colsky, A.S., Kirsner, R.S., Kerdel, F.A. Analysis of antibiotic susceptibilities of skin wound flora in hospitalized dermatology patients. The crisis of antibiotic resistance has come to the surface. Arch Dermatol 1998; 134: 1006-1009.
11. Diekema, D.J., Pfaller, M.A., Schmitz, F.J. y cols. Survey of infections due to Staphylococcus species: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific Region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32(Suppl 2): S114-S132.
12. Graffunder, E.M., Venezia, R.A. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother 2002; 49: 999-1005.
13. Eady, E.A., Cove, J.H. Staphylococcal resistance revisited: Community-adquired methicillin resistant Staphylococcus aureus, an emerging problem for the management of skin and soft tissue infections. Curr Opin Infect Dis 2003; 16: 103-124.
14. Eron, L.J., Lipsky, B.A., Low, D.E., Nathwani, D., Tice, A.D., Volturo, G.A. Managing skin and soft tissue infections: Expert panel recommendations on key decision points. J Antimicrob Chemother 2003; 52(Suppl. S1): i13-i17.
15. Fridkin, S.K., Hageman, J.C., Morrison, M. y cols. Methicillin- resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005; 352: 1436-1444.
16. Nguyen, D.M., Mascola, L., Brancoft, E. Recurring methicillin- resistant Staphylococcus aureus infections in a football team. Emerg Infect Dis 2005; 11: 526-532.
17. Miller, L.G., Perdreau-Remington, F., Rieg, G. y cols. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005; 352: 1445-1453.
18. Deresinski, S. Methicillin-resistant Staphylococcus aureus: An evolutionary epidemiologic, and therapeutic odyssey. Clin Infect Dis 2005; 40: 562-573.
19. Bradley, S.F. Staphylococcus aureus pneumonia: Emergence of MRSA in the community. Semin Respir Crit Care Med 2005; 26: 643-649.
20. Naimi, T.S., LeDell, K.H., Como-Sabetti, K. y cols. Comparison of community and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003; 290: 2976-2984.
21. Zetola, N., Francis, J.S., Nuermberger, E.L., Bishai, W.R. Community acquired methicillin-resistant Staphylococcus aureus: An emerging threat. Lancet Infect Dis 2005; 5: 275286.
22. Hiramatsu, K., Hanaki, H., Ino, T., Yabuta, K., Oguri, T., Tenover, EC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-136.
23. Ariza, J., Pujol, M., Cabo, J. y cols. Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet 1999; 353: 1587-1588.
24. Liu, C., Chambers, H.C. Staphylococcus aureus with heterogeneous resistance to vancomycin: Epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother 2003; 47: 3040-3045.
25. Tenover, F.C., Weigel, L.M., Appelbaum, P.C. y cols. Vancomycin- resistant Staphylococcus aureus isolate from a patient in Pensylvania. Antimicrob Agents Chemother 2004; 48: 275-280.
26. Nichols, R.L., Graham, D.R., Barriere, S.L. y cols. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: Two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. J Antimicrob Chemother 1999; 44: 263-273.
27. Stevens, D.L., Smith, L.G., Bruss, J.B. y cols. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000; 44: 3408-3413.
28. Weigelt, J., Kaafarani, H.M.A., Itani, K.M.F., Swanson, R.N. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg 2004; 188: 760-766.
29. Lipski, B.A., Itani, K., Norden, C. and Linezolid Diabetic Food Infections Study Group. Treating foot infections in diabetic patients: A randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxillin-clavulanate. Clin Infect Dis 2004; 38: 17-24.
30. Sharpe, J.N., Shively, E.H., Polk, H.C. Jr. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg 2005; 189: 425-428.
31. Itani, K.M.F., Weigelt, J., Li, J.Z., Duttagupta, S. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2005; 26: 442-448.
32. Arbeit, R.D., Maki, D., Tally, F.P., Campanaro, E., Eisenstein, B.I. and the Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38: 1673-1681.
33. Jauregui, L.E., Babazadeh, S., Seltzer, E. y cols. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005; 41: 1407-1415.
34. Stryjewski, M.E., O'Riordan, W.D., Lau, W.K. y cols. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis 2005; 40: 1601-1607.
35. Ellis-Grosse, E.J., Babinchak, T., Dartois, N., Rose, G., Loh, E. for the Tigecycline 300 and 305 cSSSI Study Groups. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: Results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41: S341-S353.
36. DiNubile, M.J., Lipsky, B.A. Complicated infections of skin and skin structures: When the infection is more than skin deep. J Antimicrob Chemother 2004; 53(Suppl. S2): ii37-ii50.
37. Loudon, I. Necrotising fasciitis, hospital gangrene, and phagedena. Lancet 1994; 344: 1416-1419.
38. Sánchez, U., Peralta, G. Infecciones necrosantes de partes blandas: Nomenclatura y clasificación. Enferm Infecc Microbiol Clin 2003; 21: 196-199.
39. Swartz, M.N. Cellulitis. N Engl J Med 2004; 350: 904-912.
40. Nichols, R.L., Florman, S. Clinical presentations of soft tissue infections and surgical site infections. Clin Infect Dis 2001; 33(Suppl. 2): S84-S93.
41. Lewis, R.T. Necrotizing soft-tissue infections. Infect Dis Clin North Am 1992; 6: 693-703.
42. Trent, J.T., Kirsner, R.S. Necrotizing fasciitis. Wounds 2002; 14: 284-292.
43. Smith, A.J., Daniels, T., Bohnen, J.M. Soft tissue infections and the diabetic foot. Am J Surg 1996; 172(Suppl. 6A): 7S-12S.
44. Wall, D., De Virgilio, C., Black, S., Klein, S. Objective criteria may assist in distinguishing necrotizing fasciitis from nonnecrotizing soft tissue infection. Am J Surg 2000; 179: 17-21.
45. Wong, C.H., Lum, P.N.L., Wong, S.S.Y., Cheng, V.C., Yuen, K.Y. The diagnosis of necrotizing fascitis. Curr Opin Infect Dis 2005; 18: 101-106.
46. Vinh, D.C., Embil, J.M. Rapidly progressive soft tissue infections. Lancet Infect Dis 2005; 5: 501-513.
47. Carratalá, J., Rosón, B., Fernández-Sabe, N. y cols. Factors associated with complications and mortality in adult hospitalized for infectious cellulites. Eur J Crit Microb Infect Dis 2003; 22: 151-157.
48. Laube, S., Farrell, A.M. Bacterial skin infections in the elderly: Diagnosis and treatment. Drugs and Aging 2002; 19: 331-342.
49. Struk, D.W., Munk, P.L., Lee, M.J., Ho, S.G., Worsley, D.F. Imaging of soft tissue infections. Radiol Clin North Am 2001; 39: 277-303.
50. Chao, H.C., Lin, S.J., Huang, Y.C., Lin, T.Y. Sonographic evaluation of cellulitis in children. J Ultrasound Med 2000; 19: 743-749.
51. Boutin, R.D., Brossmann, J., Sartoris, D.J., Reilly, D., Resnick, D. Update on imaging of orthopedic infections. Orthop Clin North Am 1998; 29: 41-66.
52. Schmid, M.R., Kossmann, T., Duewell, S. Differentiation of necrotizing fasciitis and cellulitis using MR imaging. Am J Roentgenol 1998; 170: 615-620.
53. Chapnick, E.K., Abter, E.I. Necrotizing soft-tissue infections. Infect Dis Clin North Am 1996; 10: 835-855.
54. Simonart, T., Simonart, J.M., Derdelinckx, I. y cols. Value of standard laboratory tests for the early recognition of group A β-hemolytic streptococcal necrotizing fascitis. Clin Infect Dis 2001; 32: E9-E12.
55. Sutherland, M.E., Meyer, A.A. Necrotizing soft-tissue infections. Surg Clin North Am 1994; 74: 591-607.
56. Stamenkovic, I., Lew, P.D. Early recognition of potentially fatal necrotizing fasciitis: The use of frozen-section biopsy. N Engl J Med 1984; 310: 1689-1693.
57. Sapico, F.L., Witte, J.L., Canawati, N.H., Montgomerie, J.Z., Bessman, A.N. The infected foot of the diabetic patient: Quantitative microbiology and analysis of clinical features. Rev Infect Dis 1984; 6 (Suppl. 1): S171-S176.
58. Sachs, M.K. The optimum use of needle aspiration in the bacteriologic diagnosis of cellulitis in adults. Arch Intern Med 1990; 150: 1907-1912.
59. Howe, P.M., Fajardo, J.E., Orcutt, M.A. Etiologic diagnosis of cellulitis: Comparison of aspirates obtained from the leading edge and the point of maximal inflammation. Pediatr Infect Dis J 1987; 6: 685-686.
60. Perl, B., Gottehrer, N.P., Ravek, D., Schlesinger, Y., Rudensky, B., Yinnon, A.M. Cost-effectiveness of blood cultures for adult patients with cellulitis. Clin Infect Dis 1999; 29: 1483-1488.
61. Brown, J., Shriner, D.L., Schwartz, R.A., Janniger, C.K. Impetigo: An update. Int J Dermatol 2003; 42: 251-255.
62. Britton, J.W., Fajardo, J.E., Krafte-Jacobs, B. Comparison of mupirocin and erythromycin in the treatment of impetigo. J Pediatr 1990; 117: 827-829.
63. Koning, S., Verhagen, A.P., Van Suijlekom-Smit, L.W., Morris, A., Butler, C.C., Van der Wouden, J.C. Interventions for impetigo. Cochrane Database Syst Rev 2004; 2: CD003261.
64. George, A., Rubin, G. A systematic review and meta-analysis of treatments for impetigo. Br J Gen Pract 2003; 53: 480-487.
65. Denis, O., Simonart, T. Involvement of Staphylococcus aureus in erysipelas. Dermatology 2006; 212: 1-3.
66. Albrich, W.C., Monnet, D.L., Harbarth, S. Antibiotic selection pressure and resistance in Streptococcus pneumoniae and Streptococcus pyogenes. Emerg Infect Dis 2004; 10: 514-517.
67. Pérez-Trallero, E., García de la Fuente, C., García Rey, C. y cols. Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob Agents Chemother 2005; 49: 1965-1972.
68. Swartz, M.N. Clinical practice. Cellulitis. New Engl J Med 2004; 350: 904-912.
69. Duvanel, T., Auckenthaler, R., Rohner, P., Harms, M., Saurat, H.J. Quantitative cultures of biopsy specimens from cutaneous cellulitis. Arch Intern Med 1989; 149: 293-296.
70. Stevens, D.L., Bisno, A.L., Chambers, H.F. y cols. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41: 1373-1406.
71. Gemmell, C.G., Edwards, D.I., Fraise, A.P., Could, F.K., Ridgway, G.L., Warren, R.E. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 2006; 57: 589-608.
72. Hepburn, M.J., Dooley, D.P., Skidmore, P.J., Ellis, M.W., Starnes, W.F., Hasenwinkle, W.C. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med 2004; 164: 1669-1674.
73. Bickels, J., Ben-Sira, L., Kessler, A., Wientroub, S. Primary pyomyositis. J Bone Joint Surg Am 2002; 84: 2277-2286.
74. Nauta, E.H., Mattie, H. Dicloxacillin and cloxacillin: Pharmacokinetics in healthy and hemodialysis subjects. Clin Pharmacol Ther 1976; 20: 98-108.
75. Dellinger, E.P. Severe necrotizing soft-tissue infections. Multiple disease entities requiring a common approach. JAMA 1981; 246: 1717-1721.
76. Lewis, R.T. Soft tissue infections. World J Surg 1988; 22: 146-151.
77. Stone, H.H., Martin, J.D. Synergistic necrotizing cellulitis. Ann J Surg 1972; 175: 702-711.
78. Sitges-Serra, A. Severe soft tissue infections: A syndrome-based approach. En: Rello, J., Vallès, J., Kollef, M. (Eds.). Critical care infectious diseases. Kluwer Academic Publishers, Norwell 2001; 833-844.
79. Cline, K.A., Turnbull, T.L. Clostridial myonecrosis. Ann Emerg Med 1985; 14: 459-466.
80. Stevens, D.L. Invasive group A streptococcus infections. Clin Infect Dis 1992; 14: 2-211.
81. Bisno, A.L., Stevens, D.L. Streptococcal infections of skin and soft tissues. N Engl J Med 1996; 334: 240-245.
82. Currie, B.J. Group A Streptococcal infections of the skin: Molecular advances but limited therapeutic progress. Curr Opin Infect Dis 2006; 19: 132-138.
83. Gold, W.L., Salit, I.E. Aeromonas hydrophila infections of skin and soft tissue: Report of 11 cases and review. Clin Infect Dis 1993; 16: 69-74.
84. Bilton, B.D., Zibari, G.B., McMillan, R.W., Aultman, D.F., Dunn, G., McDonald, J.C. Agressive surgical management of necrotizing fascitis serves to decrease mortality: A retrospective study. Am Surg 1998; 64: 397-400.
85. Singh, G., Sinha, S.K., Adhikary, S., Babu, K.S., Ray, P., Khanna, S.K. Necrotising infections of soft tissues: A clinical profile. Eur J Surg 2002; 168: 366-371.
86. Tan, J.S., Wishnow, R.M., Talan, D.A., Duncanson, F.P., Norden, C.W. Treatment of hospitalizad patients with complicated skin and skin structure infections: Double-blind, randomized, multicenter study of piperacillin- tazobactam versus ticarcillin-clavulanate. The piperacillin-tazobactam skin and skin structure study group. Antimicrob Agents Chemother 1993; 37: 1580-1586.
87. Nichols, R.L., Smith, J.W., Geckler, R.W., Wilson, S.E. Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections. South Med J 1995; 88: 397-404.
88. Graham, D.R., Lucasti, C., Malafaia, O. y cols. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: Results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis 2002; 34: 1460-1468.
89. Bradsher, R.W. Jr., Snow, R.M. Ceftriaxone treatment of skin and soft tissue infections in a once daily regimen. Am J Med 1984; 77: 63-67.
90. Gentry, L.O., Ramírez-Ronda, C.H., Rodríguez-Noriega, E., Thadepalli, H., Del Rosal, P.L., Ramírez, C. Oral ciprofloxacin vs parenteral cefotaxime in the treatment of difficult skin and skin structure infections: A multicenter trial. Arch Intern Med 1989; 149: 2579-2583.
91. Nicodemo, A.C., Robledo, J.A., Jasovich, A., Neto, W. A multicentre, double-blind, randomized study comparing the efficacy and safety of oral levofloxacin versus ciprofloxacin in the treatment of uncomplicated skin and skin structure infections. Int J Clin Pract 1998; 52: 69-74.
92. Tarshis, G.A., Miskin, B.M., Jones, T.M. y cols. Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: Double-blind, multicenter, randomized study. Antimicrob Agents Chemother 2001; 45: 2358-2362.
93. Muijsers, R.B., Jarvis, B. Moxifloxacin in uncomplicated skin and skin structure infections. Drugs 2002; 62: 967-973.
94. Stevens, D.L., Maier, K.A., Laine, B.M., Mitten, J.E. Comparison of clindamycin, rifampin, tetracycline, metronidazole, and penicillin for efficacy in prevention of experimental gas gangrene due to Clostridium perfringens. J Infect Dis. 1987; 155: 220-228.
95. Stevens, D.L., Laine, B.M., Mitten, J.E. Comparison of single and combination antimicrobial agents for prevention of experimental gas gangrene caused by Clostridium perfringens. Antimicrob Agents Chemother 1987; 31: 312-316.
96. Stevens, D.L., Madara-Kelly, K., Richards, D. In vitro antimicrobial effects of various combinations of penicillin and clindamicin against four strains of Streptococcus pyogenes. Antimicrob Agents Chemother 1998; 42: 1266-1268.
97. Clark, L.A., Moon, R.E. Hyperbaric oxygen in the treatment of life-threatening soft-tissue infections. Respir Care Clin North Am 1999; 5: 203-219.
98. Wu, W., Lieber, M.J. Hyperbaric oxygen therapy: Ten common questions related to the management of severe necrotizing skin and soft-tissue infections. Infect Dis Clin Pract 2001; 10: 429-434.
99. Smith, P.F., Meadowcroft, A.M., May, D.B. Treating mammalian bite wounds. J Clin Pharm Ther 2000; 25: 85-99.
100. Taplitz, R.A. Managing bite wounds. Currently recommended antibiotics for treatment and prophylaxis. Postgrad Med 2004; 116: 49-52, 55-56, 59.
101. Morgan, M. Hospital management of animal and human bites. J Hosp Infect 2005; 61: 1-10.
102. Jofré, L., Prêt, C., Abarca, K. y cols. Recomendaciones para el manejo de mordeduras ocasionadas por animales. Rev Chil Infect 2006; 23: 20-34.
103. Merchant, R.C., Fuerch, J., Becker, B.M., Mayer, K.H. Comparison of the epidemiology of human bites evaluated at three US pediatric emergency departments. Pediat Emerg Care 2005; 21: 833-838.
104. Goldstein, E.J. New horizons in the bacteriology, antimicrobial susceptibility and therapy of animal bite wounds. J Med Microbiol 1998; 47: 95-97.
105. Talan, D.A., Citron, D.M., Abrahamian, F.M., Moran, G.J., Goldstein, E.J. Bacteriologic analysis of infected cat and dog bites. N Engl J Med 1999; 340: 85-92.
106. Abrahamian, F.M. Dog bites: Bacteriology, management, and prevention. Curr Infect Dis Rep 2000; 2: 446-453.
107. Brook, I. Management of human and animal bite wounds: An overview. Adv Skin Wound Care 2005; 18: 197-203.
108. Bartholomew, C.F., Jones, A.M. Human bites: A rare risk factor for HIV transmission. AIDS 2006; 20: 631-632.
109. Bass, J.W., Vincent, J.M., Person, D.A. The expanding spectrum of Bartonella infections: II. Cat-scratch disease. Pediatr Infect Dis 1997; 16: 163-179.
110. Stefanopoulos, P.K., Tarantzopoulou, A.D. Facial bite wounds: Management update. Int J Oral Maxillofac Surg 2005; 34: 464-472.
111. Goldstein, E.J., Reinhardt, J.F., Murray, P.M., Finegold, S.M. Outpatient therapy of bite wounds. Demographic data, bacteriology, and a prospective, randomized trial of amoxicillin/clavulanic acid versus penicillin +/- dicloxacillin. Int J Dermatol 1987; 26: 123-127.
112. Palacio, J., León, M., García-Belenguer, S. Aspectos epidemiológicos de las mordeduras caninas. Gac Sanit 2005; 19: 50-58.
113. Almeda, J., Casabona, J., Allepuz, A. y cols. Guía de actuación para la profilaxis postexposición no ocupacional del VIH. Recomendaciones GESIDA/CEESCAT/PNS. Enferm Infecc Microbiol Clin 2002; 20: 391-400.
114. Horan, T.C., Gaynes, R.P., Martone, W.J., Jarvis, W.R., Emori, T.G. CDC definitions of nosocomial surgical site infections 1992: A modification of CDC definitions of surgical wound infections. Infect Control Hosp Epidemiol 1992; 13: 606-608.
115. Fry, D. The economic costs of surgical site infection. Surg Infect 2002; 3 (Suppl.): S37-S43.
116. Barie, P. Surgical site infections: Epidemiology and prevention. Surg Infect 2002; 3 (Suppl.): S9-S21.
117. Cainzos, M. Surgical infection control. Surg Infect 2005; 6: 7-17.
118. Iñigo, J., Bermejo, B., Oronoz, B. y cols. Infección del sitio quirúrgico en un servicio de cirugía general. Análisis de cinco años y valoración del índice National Nosocomial Infection Surveillance (NNIS). Cir Esp 2006; 79: 224-230.
119. National Nosocomial Infections Surveillance N. System Report, data summary from January 1992 through June 2003. Am J Infect Control 2003; 31: 481-498.
120. Emori, T., Gaynes, R. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 1993; 6: 428-442.
121. Bernardo, K., Pakulat, N., Fleer, S. y cols. Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression. Antimicrob Agents Chemother 2004; 48: 546-555.
122. Howell-Jones, R.S., Wilson, M.J., Hill, K.E., Howard, A.J., Price, P.E., Thomas, D.W. A review of the microbiology, antibiotic usage and resistance in chronic skin wounds. J Antimicrob Chemother 2005; 55, 143-149.
123. Parish, L.C., Witkowski, J.A. The infected decubitus ulcer. Int J Dermatol 1989; 28: 643-647.
124. Livesley, N.J., Chow, A.W. Infected pressure ulcers in elderly individuals. Clin Infect Dis 2002; 35: 1390-1396.
125. Wolfson, J.S., Sober, A.J., Rubin, R.H. Dermatologic manifestations of infections in immunocompromised patients. Medicine (Balt) 1985; 64: 115-133.
126. López, F.A., Sanders, C.V. Dermatologic infections in the immunocompromised (non HIV) host. Infect Dis Clin North Am 2001; 15: 671-702.
127. García Rodríguez, J.A., Gobernado, M., Gomis, M. y cols. Guía clínica para la evaluación y el tratamiento del paciente neutropénico con fiebre. Rev Esp Quimioterap 2001; 14: 75-83.
128. Marr, K.A., Seidel, K., White, T.C., Bowden, R.A. Candidemia in allogeneic blood and marrow transplant recipients: Evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181: 309-316.
129. Ichiki, Y., Hirose, M., Akiyama, T., Esaki, C., Kitajima, Y. Skin infection caused by Mycobacterium avium. Br J Dermatol 1997; 136: 260-263.
130. Neuville, S., Dromer, F., Morin, O., Dupont, B., Ronin, O., Lortholary, O. Primary cutaneous cryptococcosis: A distinct clinical entity. Clin Infect Dis 2003; 36: 337-347.
131. Anderson, D.J., Schmidt, C., Goodman, J., Pomeroy, C. Cryptococcal disease presenting as cellulitis. Clin Infect Dis 1992; 14: 666-672.
132. Simon, M.S., Cody, R.L. Cellulitis after axillary lymph node dissection for carcinoma of the breast. Am J Med 1992; 93: 543.
133. Brewer, V.H., Hahn, K.A., Rohrback, B.W. y cols. Risk factors analysis for breast cellulitis complicating breast conservation therapy. Clin Infect Dis 2000; 31: 654.
134. Dankert, J., Bouma, J. Recurrent acute leg cellulitis after hysterectomy with pelvic lymphadenectomy. Br J Obstet Gynaecol 1987; 94: 788.
135. Bouma, J., Dankert, J. Recurrent acute leg cellulitis in patients after radical vulvectomy. Gynecol Oncol 1988; 29: 50.
136. Baddour, L.M., Bisno, A.L. Recurrent cellulitis after saphenous venectomy for coronary bypass surgey. Ann Intern Med 1982; 97: 493.
137. Hook, E.W. III, Hooton, T.M., Horton, C.A. y cols. Microbiologic evaluation of cutaneous cellulitis in adults. Arch Intern Med 1986; 146: 295.